Femasys vs Intelligent Bio Solutions
Intelligent Bio Solutions reported revenue of $4 million in fiscal 2026, 1.8 times Femasys' $2 million in fiscal 2025. Femasys' revenue grew 40.8% in its latest year, and Intelligent Bio Solutions' grew 38.1%. Femasys had an operating margin of -767.0%, against -299.1% at Intelligent Bio Solutions. Free cash flow was −$19 million at Femasys and −$12 million at Intelligent Bio Solutions. Their fiscal years end in different months (December 31 and June 30), so the periods don't line up exactly.
Side by side
| Femasys | Intelligent Bio Solutions | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2026, Jun 30, 2026 |
| Revenue | $2M | $4M |
| Revenue growth | 40.8% | 38.1% |
| Revenue growth a year, last 5 years | 18.1% | 16.0% |
| Gross margin | 62.0% | 48.6% |
| Operating margin | −767.0% | −299.1% |
| Net margin | −812.3% | −294.9% |
| Free cash flow | −$19M | −$12M |
| Free cash flow margin | −837.9% | −285.9% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 77.6% | 179.3% |
| Last close | $1.26 | $1.51 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $74,000, sold $0 | — |
| Piotroski F-score | 2 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
FemasysIntelligent Bio Solutions
Operating margin
Percent of revenue
FemasysIntelligent Bio Solutions
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
FemasysIntelligent Bio Solutions
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Femasys and Intelligent Bio Solutions pages.